Tenet Healthcare 二季度业绩大幅超预期并上调全年指引，但消息已在盘前/盘中充分交易

Intel down as investors lock in gains despite strongest revenue growth in 15 years
Introduction & Market Context
Tenet Healthcare Corporation (NYSE:THC) presented its second quarter 2026 earnings results on July 23, 2026, showcasing performance that significantly exceeded Wall Street expectations and prompting the company to raise its full-year outlook by $295 million at the midpoint. The Dallas-based hospital operator and ambulatory surgery center platform reported consolidated adjusted EBITDA of $1.304 billion, representing 16.3% growth year-over-year, while adjusted diluted earnings per share surged 52.2%.
The strong results drove shares up 17.6% to $234.03 in after-hours trading, approaching the company’s 52-week high of $247.21. With adjusted EPS of $6.12 crushing the analyst consensus of $4.23 by 44.7%, and revenue of $5.63 billion topping estimates by 3.7%, the quarter reflected what management characterized as "fundamental outperformance" across both its hospital and ambulatory segments.
Quarterly Performance Highlights
The following slide from Tenet’s presentation summarizes the company’s second quarter achievements, highlighting double-digit growth across key profitability metrics:
Tenet’s consolidated adjusted EBITDA margin expanded to 23.2% in the second quarter, up from 21.3% in the prior-year period, demonstrating improved operating leverage. Net operating revenues reached $5.628 billion, up 6.8% from $5.271 billion in Q2 2025, while the company maintained disciplined cost control with salaries, wages and benefits declining as a percentage of revenue to 39.6% from 41.0% year-over-year.
The quarter’s performance was driven by higher-acuity services, improved operating efficiency, and what CEO Saum Sutaria described as a "transformed portfolio" more focused on growth markets. Management attributed the results to strong execution across both business segments, with particular strength in hospital volumes and ambulatory surgery center case growth.
Ambulatory Surgery Center Platform Drives Growth
United Surgical Partners International (USPI), Tenet’s ambulatory surgery center platform, continued its track record of consistent mid-teens growth. The segment delivered 8.8% adjusted EBITDA growth in the second quarter, representing approximately 25% of the company’s full-year 2026 EBITDA guidance. Same-facility revenue growth reached 5.0%, while the segment maintained its industry-leading 39.0% adjusted EBITDA margin.
The company’s presentation highlighted USPI’s impressive long-term growth trajectory, as illustrated in the following chart:
USPI has achieved a 15.7% revenue compound annual growth rate from 2019 to 2025, growing from $2.158 billion to $5.172 billion. Adjusted EBITDA expanded at a 14.6% CAGR over the same period, reaching $2.026 billion in 2025 while maintaining consistent margins near 40%.
The platform’s organic growth has been equally impressive. As shown in the next chart, USPI has delivered a 6.1% same-facility system-wide revenue CAGR from 2015 through the first half of 2026:
Management emphasized USPI’s leadership in strategy and execution, noting 237 service line additions year-to-date in 2026 and 9.6% same-facility ASC total joints growth in the second quarter. The company is expanding high-acuity cases including orthopedics, robotics, urology, bariatrics and cardiovascular procedures.
USPI’s service mix and clinical quality metrics further support its market position. The platform’s case mix is well-diversified, with gastrointestinal procedures representing 42%, musculoskeletal 30%, ophthalmology 11%, and other specialties 17%. The platform achieved a 96.7 overall patient experience score in 2025.
The company’s acquisition strategy has delivered significant returns on invested capital. USPI’s facility count expanded from 267 at the end of 2017 to 564 as of June 30, 2026, with acquisitions achieving effective multiples of 5-7x compared to initial acquisition multiples of 8-10x, generally realized over a three-year period. De novo facilities have exceeded targeted effective multiples of less than 2.0x.
During the second quarter, Tenet acquired two ambulatory centers and opened one de novo facility, with management expecting more than $300 million of USPI M&A deployment in 2026.
Hospital Segment Performance Accelerates
Tenet’s hospital segment delivered particularly strong results in the second quarter, with adjusted EBITDA growing 22.3% year-over-year to reach an 18.0% adjusted EBITDA margin. The segment reported 2.6% adjusted admissions growth over Q2 2025, reflecting market share gains and strong demand for higher-acuity services.
Management credited the hospital performance to a combination of volume growth, improved payer mix, and operational efficiency initiatives. The company’s focus on technology, robotics, and targeted surgical hospital expansion in higher-acuity services appears to be yielding results, even as the broader healthcare environment remains mixed.
One headwind the company faced was a 17% decline in exchange-related revenue during the quarter, as enhanced premium tax credits expired and some patients moved to uninsured status. However, management indicated this matched internal expectations and that the company is prepared for similar pressure in the second half of the year.
Raised Guidance Reflects Strong Fundamentals
Based on first-half outperformance and expectations for continued strength, Tenet raised its full-year 2026 adjusted EBITDA outlook to a range of $4.83 billion to $5.03 billion, representing a $295 million increase at the midpoint from previous guidance. The company also increased its adjusted free cash flow outlook (less non-controlling interests) by $225 million to a range of $1.825 billion to $2.055 billion.
The following bridge illustrates the drivers of Tenet’s 2026 adjusted EBITDA outlook compared to normalized 2025 performance:
The outlook reflects 11.6% anticipated growth versus normalized 2025 performance, driven by $582 million in growth and cost efficiencies. The ambulatory segment is expected to grow 8.1%, while the hospital segment is projected to expand 14.5% compared to 2025 normalized performance.
Management’s confidence in raising guidance stems from multiple factors, as shown in the bridge from previous guidance:
The $295 million increase includes $140 million from incremental supplemental Medicaid revenue programs approved after the previous outlook, $97 million from first-half 2026 EBITDA outperformance, and $58 million from expected second-half 2026 EBITDA improvement.
For the full year 2026, Tenet now expects net operating revenues of $21.9 billion to $22.5 billion, with consolidated adjusted EBITDA margins of 22.1% to 22.4%. The company projects ambulatory same-facility system-wide revenues to grow 3% to 6%, with inpatient admissions and adjusted admissions each up 1% to 2%.
Capital Deployment and Shareholder Returns
Tenet’s strong cash generation and improved balance sheet position have enabled aggressive capital deployment, particularly through share repurchases. The company’s capital position as of June 30, 2026, is illustrated in the following graphic:
The company generated $444 million of adjusted free cash flow in the second quarter ($243 million after non-controlling interest distributions), bringing year-to-date adjusted free cash flow to $1.422 billion. Cash on hand stood at $2.17 billion with $1.9 billion of unused line of credit capacity, providing substantial financial flexibility.
During the second quarter, Tenet repurchased approximately 5.68 million shares for $1.042 billion, bringing year-to-date repurchases to 7.02 million shares for $1.36 billion. The board of directors authorized a $2.0 billion increase to the company’s share repurchase program, leaving $2.13 billion in remaining authorization.
The company’s leverage ratio improved to 2.33x EBITDA (2.90x EBITDA less non-controlling interests) as of June 30, 2026. This represents dramatic deleveraging from historical levels, as shown in the following chart:
Tenet has reduced its leverage ratio from 5.86x EBITDA in 2017 to 2.33x in the second quarter of 2026, a transformation management attributed to "substantial reduction in leverage following significant performance improvement and hospital sales."
The company’s capital deployment priorities balance growth investment with shareholder returns:
Management outlined a baseline intention of $250 million per year for ASC platform M&A and de novo investments, continued investment in hospital technology and robotics, ongoing share repurchases, and a commitment to maintaining a deleveraged balance sheet through earnings growth and debt repayment.
Challenges and Risk Factors
Despite the strong quarterly performance, Tenet faces several headwinds. The expiration of enhanced premium tax credits has resulted in exchange enrollment declines, with exchange revenue falling 17% in the second quarter. Management expects this pressure to continue through the second half of 2026 at a similar pace, with some patients moving to uninsured status, which can negatively impact collections and revenue mix.
Proposed regulatory changes to HOPPS (Hospital Outpatient Prospective Payment System) and 340B drug pricing programs could affect hospital outpatient economics and ASC pricing. Additionally, some of the company’s revenue growth came from supplemental Medicaid programs and timing items that may not repeat at the same pace.
Commercial rate negotiations remain ongoing, and professional fees continue to rise, creating pressure on margins. The company must also navigate competitive dynamics in local markets while managing the complexity of supplemental Medicaid programs across different states.
Management addressed these concerns during the earnings call, emphasizing that exchange-related pressure matched expectations and that the company’s diversified portfolio, focus on higher-acuity services, and operational improvements position it to navigate these challenges while maintaining growth.
With its raised guidance, strong cash generation, and continued momentum in both ambulatory and hospital segments, Tenet’s second quarter presentation portrayed a company executing on its strategic transformation while delivering substantial returns to shareholders.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.